Celltech plans Oxford Glyco bid to break up £110m CAT merger

Cambridge Antibody Technology, the UK biotechnology company, yesterday said it was pressing ahead with plans to merge with its smaller rival, Oxford GlycoSciences, despite news that Celltech, Britain's biggest biotech group was preparing a rival bid for the Oxford-based company.

CAT, which announced plans for an agreed takeover of OGS last month, said it had received "positive feedback" from the company's shareholders for its proposed £110m all-share offer.

The move came after Celltech emerged as another likely buyer of OGS. Celltech is thought to be close to launching an all-cash offer pitched slightly higher than CAT's all-share bid. The bid could wreck the merger plans of the two smaller companies.

Celltech refused to comment on its plans, but it is believed to have asked its advisers, Cazenove and JP Morgan, to carry out a careful assessment of OGS's business.

Celltech is likely to table its own bid within the next few weeks, before OGS's shareholders vote on the CAT deal at an extraordinary general meeting on 11 March.

If Celltech prevails in the bidding battle, the enlarged company is likely to be run by Goran Ando. Mr Ando, currently the research and development director at Pharmacia, is widely tipped to become Celltech's new chief executive when Peter Fellner moves up to become non-executive chairman next month.

OGS said last month its two largest shareholders, Invesco and Fidelity, which hold a combined 29 per cent, supported CAT's offer. Yesterday it said that deal remained the only one on the table, making it "in the best interest of our shareholders" to press ahead.

The two companies argued when they unveiled their deal on 23 January that their drug discovery technologies would fit well together.

OGS is an expert in proteomics, and as such is able to identify proteins in the human body which may be linked to disease. CAT's expertise is in the identification and manufacture of antibodies, which are formed in the human body to fight disease.

The enlarged group would have seven products in trials on humans and another seven in pre-clinical development.

Both companies would also bring one finished product to the merger. CAT's Humira is a treatment for rheumatoid arthritis which is ready for launch in the US, and OGS's Zavesca treats Gaucher disease, a rare condition in which the body has difficulty breaking down fat.

CAT's offer was well received in the City for its strategic fit but not seen as a generous valuation of OGS, which has a market capitalisation of only £95m but a cash pile of £130m.

The CAT offer values OGS at a 30 per cent discount to its cash pile. Critics have said the deal is also, in effect, a rights issue for CAT, which will have to issue shares in order to complete the purchase.

Celltech, which is also developing an arthritis drug, is set to make £51m of profits this year. Financially, it could outgun CAT and also believes OGS's shareholders will favour the fact that it is offering cash.

OGS' shares have advanced 28 per cent this year, and closed at 172p on Friday.

Start your day with The Independent, sign up for daily news emails
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Recruitment Genius: Compliance Manager

£40000 - £60000 per annum: Recruitment Genius: A Compliance Manager is require...

SThree: Talent Acquisition Consultant

£22500 - £27000 per annum + OTE £45K: SThree: Since our inception in 1986, STh...

Recruitment Genius: Experienced Financial Advisers and Paraplanners

Negotiable: Recruitment Genius: This extremely successful and well-established...

Guru Careers: FX Trader / Risk Manager

Competitive with monthly bonus: Guru Careers: We are seeking an experienced FX...

Day In a Page

How to stop an asteroid hitting Earth: Would people co-operate to face down a global peril?

How to stop an asteroid hitting Earth

Would people cooperate to face a global peril?
Just one day to find €1.6bn: Greece edges nearer euro exit

One day to find €1.6bn

Greece is edging inexorably towards an exit from the euro
New 'Iron Man' augmented reality technology could help surgeons and firefighters, say scientists

'Iron Man' augmented reality technology could become reality

Holographic projections would provide extra information on objects in a person's visual field in real time
Sugary drinks 'are killing 184,000 adults around the world every year'

Sugary drinks are killing 184,000 adults around the world every year

The drinks that should be eliminated from people's diets
Pride of Place: Historians map out untold LGBT histories of locations throughout UK

Historians map out untold LGBT histories

Public are being asked to help improve the map
Lionel, Patti, Burt and The Who rock Glasto

Lionel, Patti, Burt and The Who rock Glasto

This was the year of 24-carat Golden Oldies
Paris Fashion Week

Paris Fashion Week

Thom Browne's scarecrows offer a rare beacon in commercial offerings
A year of the caliphate:

Isis, a year of the caliphate

Who can defeat the so-called 'Islamic State' – and how?
Marks and Spencer: Can a new team of designers put the spark back into the high-street brand?

Marks and Spencer

Can a new team of designers put the spark back into the high-street brand?
'We haven't invaded France': Italy's Prime Minister 'reclaims' Europe's highest peak

'We haven't invaded France'

Italy's Prime Minister 'reclaims' Europe's highest peak
Isis in Kobani: Why we ignore the worst of the massacres

Why do we ignore the worst of the massacres?

The West’s determination not to offend its Sunni allies helps Isis and puts us all at risk, says Patrick Cockburn
7/7 bombings 10 years on: Four emergency workers who saved lives recall the shocking day that 52 people were killed

Remembering 7/7 ten years on

Four emergency workers recall their memories of that day – and reveal how it's affected them ever since
Humans: Are the scientists developing robots in danger of replicating the hit Channel 4 drama?

They’re here to help

We want robots to do our drudge work, and to look enough like us for comfort. But are the scientists developing artificial intelligence in danger of replicating the TV drama Humans?
Time to lay these myths about the Deep South to rest

Time to lay these myths about the Deep South to rest

'Heritage' is a loaded word in the Dixie, but the Charleston killings show how dangerous it is to cling to a deadly past, says Rupert Cornwell
What exactly does 'one' mean? Court of Appeal passes judgement on thorny mathematical issue

What exactly does 'one' mean?

Court of Appeal passes judgement on thorny mathematical issue